EP3342405A1 — Controlled release 25-hydroxyvitamin d
Assigned to Opko Ireland Global Holdings Ltd · Expires 2018-07-04 · 8y expired
What this patent protects
The invention provides 25-hydroxyvitamin D for use in the treatment of hyperparathyroidism by controlled release. The formulation is used to treat secondary hyperparathyroidism in a human patient having Chronic Kidney Disease (CKD). A controlled release, oral dosage form of 25-hy…
USPTO Abstract
The invention provides 25-hydroxyvitamin D for use in the treatment of hyperparathyroidism by controlled release. The formulation is used to treat secondary hyperparathyroidism in a human patient having Chronic Kidney Disease (CKD). A controlled release, oral dosage form of 25-hydroxyvitamin D is administered in combination with one or more agent selected from: one or more calcium salts, bisphosphonates, calcimimetics, nicotinic acid, iron, phosphate binders, glycemic control agents, hypertension control agents, antineoplastic agents, inhibitors of CYP24, and inhibitors of other cytochrome P450 enzymes that can degrade vitamin D agents.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.